Applicant, as named in the Orange Book

Biomarin Pharm

Next listed expiry: Kuvan on 1 May 2033. 2 products with live protection, 1 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Kuvan · 2 strengths sapropterin dihydrochloride	sapropterin dihydrochloride	205065	1 May 2033	patent
Voxzogo · 3 strengths vosoritide	vosoritide	214938	11 Jul 2042	patent, carve-out possible

Products without listed protection (1)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Kuvan sapropterin dihydrochloride	sapropterin dihydrochloride	022181	open now	no listed protection